KEYTRUDA is an immunotherapy that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, helping the immune system to help detect and fight cancer cells.
The Columbia Combined Cancer Panel has been granted full approval by the New York State Department of Health.
Columbia scientists have created new decoy drugs that can intercept the deceptive growth signals that cancer cells send out.
A study of the genomes of patients with a particularly aggressive form of non-Hodgkin’s lymphoma shows that many cases are driven by alterations in the JAK/STAT3 cell signaling pathway.
Nearly 50 years after the “war on cancer” was declared in the United States, precision medicine is changing the face of cancer research.